Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis

Area of Science:

• Rheumatology and Immunology
• Dermatology
• Cell Biology

Background:

• Diffuse cutaneous systemic sclerosis (dcSSc) is a complex autoimmune disease characterized by skin fibrosis.
• Understanding the role of fibroblast phenotype and immune infiltration in disease progression is crucial for effective treatment strategies.

Purpose of the Study:

• To investigate the relationship between skin fibroblast markers (CD34, aSMA), immune cell infiltration, and disease duration in dcSSc.
• To identify predictors of clinical improvement in dcSSc patients, particularly those treated with mycophenolate mofetil (MMF).

Main Methods:

• Analysis of skin biopsies and clinical data from dcSSc patients in clinical trials.
• Semi-quantitative scoring of CD34 and aSMA; counting of immune cells (CD20+, CD3+, CD123+).
• Comparison of early (<18 months) versus later (≥18 months) disease groups; logistic regression modeling for improvement prediction.

Main Results:

• Early dcSSc showed lower CD34, higher aSMA, increased B cells, and greater improvement compared to later disease.
• Fibroblast spatial organization varied, with CD34+ in superficial and aSMA+ in deeper dermis.
• High CD34/aSMA predicted improvement in early dcSSc, while high aSMA predicted lower improvement in later dcSSc.

Conclusions:

• Fibroblast immunophenotype is associated with disease duration and predicts treatment response in dcSSc.
• Skin biopsy analysis can refine prognosis and guide patient management for dcSSc.